IPO successfully priced post re-launch
Molecular Partners has successfully priced its IPO post re-launch and lists its shares on SIX Swiss Exchange
Zurich-Schlieren, November 4, 2014. Molecular Partners AG has successfully re-launched its Initial Public Offering (IPO).
Due to strong interest and demand from both international and Swiss institutional and private investors, Molecular Partners accelerated the timetable and closed the bookbuilding process yesterday, Monday, 5pm CET.
Molecular Partners AG has successfully allocated 4,400,000 shares with a nominal value of CHF 0.10 each to institutional Swiss and international investors as well as to private domestic investors.
The offer price of CHF 22.4 per offered registered share (Offer Price) implies a post money market capitalisation of approximately CHF485 million on a fullydiluted basis (prior to exercise of the over-allotment option).
The shares (ticker symbol: MOLN) are expected to commence trading on Wednesday, 5 November on SIX Swiss Exchange.
The total base offer (Base Offer) consisted of 4,400,000 registered shares (Offered Shares) offered by Molecular Partners, comprising 4,307,000 newly-issued registered shares and 93,000 existing registered shares to be sold by the company on behalf of certain management and founding shareholders, solely in order for them to cover wealth tax liabilities in connection with the IPO.
Molecular Partners has also granted the syndicate banks an overallotment option of up to 660,000 newly-issued registered shares, which can be exercised within 30 calendar days after the first day of trading on SIX Swiss Exchange.
In relation to the issued share capital, the Offered Shares will represent approximately 22.8% of the issued share capital upon completion of the offering (prior to exercise of the over-allotment option) or approximately 25.4% of the issued share capital upon potential full exercise of the over-allotment option of up to 660,000 newly-issued registered shares, respectively.
Morgan is acting as the Sole Global Coordinator and Joint Bookrunner and UBS Investment Bank is acting as Joint Bookrunner. Cowen and Company and Bank am Bellevue are acting as Co-Managers in connection with the IPO.